These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12107346)

  • 1. Tumor removal enhances immunity induced by B7.1.
    Lee MJ; Choi SH; Shim YH; Cho SH; Kim CW
    Pathobiology; 2001; 69(5):281-8. PubMed ID: 12107346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer.
    Felzmann T; Ramsey WJ; Blaese RM
    Cancer Lett; 1999 Jan; 135(1):1-10. PubMed ID: 10077215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
    Chen L; McGowan P; Ashe S; Johnston J; Li Y; Hellström I; Hellström KE
    J Exp Med; 1994 Feb; 179(2):523-32. PubMed ID: 7507508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors.
    Li Y; Hellstrom KE; Newby SA; Chen L
    J Exp Med; 1996 Feb; 183(2):639-44. PubMed ID: 8627175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.
    Bozeman EN; Cimino-Mathews A; Machiah DK; Patel JM; Krishnamoorthy A; Tien L; Shashidharamurthy R; Selvaraj P
    Vaccine; 2013 May; 31(20):2449-56. PubMed ID: 23541884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.
    Joki T; Kikuchi T; Akasaki Y; Saitoh S; Abe T; Ohno T
    Int J Cancer; 1999 Aug; 82(5):714-20. PubMed ID: 10417770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma.
    Leong CC; Marley JV; Loh S; Milech N; Robinson BW; Garlepp MJ
    Int J Cancer; 1997 May; 71(3):476-82. PubMed ID: 9139887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of bone marrow CD8 T lymphocytes confers full protection vs. tumor growth in M-MSV/MuLV experimental model.
    Facchinetti A; Biasi G
    Immunol Lett; 2012 May; 144(1-2):78-9. PubMed ID: 22465204
    [No Abstract]   [Full Text] [Related]  

  • 10. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.
    Wen T; Kono K; Shahinian A; Kiessling R; Mak TW; Klein G
    Eur J Immunol; 1997 Aug; 27(8):1988-93. PubMed ID: 9295036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD80 and IL-2 signals cooperate in the regression of tumors transplanted in congenitally athymic mice.
    Sobota V; Indrová M; Rössner P; Bubeník J; Jandlová T
    Oncol Rep; 1999; 6(3):669-73. PubMed ID: 10203613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
    Chen L
    Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
    Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
    J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line.
    Kim SJ; Sadelain M; Lee JS; Seong RH; Yun YS; Jang YJ; Chung HY
    Cancer Immunol Immunother; 1999 Jan; 47(5):257-64. PubMed ID: 10022469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model.
    Raes G; Van Ginderachter J; Liu YQ; Brys L; Thielemans K; De Baetselier P; Geldhof A
    Cancer Immunol Immunother; 1998 Jan; 45(5):257-65. PubMed ID: 9439649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
    Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
    Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
    Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.
    Rosato A; Zambon A; Macino B; Mandruzzato S; Bronte V; Milan G; Zanovello P; Collavo D
    Int J Cancer; 1996 Mar; 65(6):847-51. PubMed ID: 8631602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy for murine glioma using tumor cells genetically modified to express B7.1.
    Morioka J; Kajiwara K; Yoshikawa K; Ideguchi M; Uchida T; Suzuki M
    Neurosurgery; 2004 Jan; 54(1):182-9; discussion 189-90. PubMed ID: 14683556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.